ATE249244T1 - Aktivierte verbindungen und verfahren zur herstellung und reiningung - Google Patents

Aktivierte verbindungen und verfahren zur herstellung und reiningung

Info

Publication number
ATE249244T1
ATE249244T1 AT96944251T AT96944251T ATE249244T1 AT E249244 T1 ATE249244 T1 AT E249244T1 AT 96944251 T AT96944251 T AT 96944251T AT 96944251 T AT96944251 T AT 96944251T AT E249244 T1 ATE249244 T1 AT E249244T1
Authority
AT
Austria
Prior art keywords
pegs
production
purification
methods
activated compounds
Prior art date
Application number
AT96944251T
Other languages
English (en)
Inventor
Prabha N Ibrahim
Robert A Baile
James Ervin Seely
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE249244T1 publication Critical patent/ATE249244T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Thermistors And Varistors (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Road Signs Or Road Markings (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
AT96944251T 1996-03-06 1996-12-06 Aktivierte verbindungen und verfahren zur herstellung und reiningung ATE249244T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/611,918 US5747639A (en) 1996-03-06 1996-03-06 Use of hydrophobic interaction chromatography to purify polyethylene glycols
PCT/US1996/019459 WO1997032607A2 (en) 1996-03-06 1996-12-06 Activated linkers and methods for making and purifying the same

Publications (1)

Publication Number Publication Date
ATE249244T1 true ATE249244T1 (de) 2003-09-15

Family

ID=24450930

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96944251T ATE249244T1 (de) 1996-03-06 1996-12-06 Aktivierte verbindungen und verfahren zur herstellung und reiningung

Country Status (11)

Country Link
US (2) US5747639A (de)
EP (1) EP0906122B1 (de)
JP (1) JP2000506851A (de)
AT (1) ATE249244T1 (de)
AU (1) AU720399B2 (de)
CA (1) CA2248006C (de)
DE (1) DE69629949T2 (de)
DK (1) DK0906122T3 (de)
ES (1) ES2206616T3 (de)
PT (1) PT906122E (de)
WO (1) WO1997032607A2 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
DK0942740T3 (da) 1996-12-06 2003-12-15 Amgen Inc Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
CN1168495C (zh) * 1997-01-15 2004-09-29 凤凰药理学公司 被修饰的肿瘤坏死因子
US7642323B2 (en) * 1997-11-06 2010-01-05 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
CN100480266C (zh) * 1998-10-16 2009-04-22 拜奥根Idec马萨诸塞公司 干扰素-β融合蛋白及用途
DK1656952T3 (da) * 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
CA2395713C (en) 2000-01-10 2012-04-10 Maxygen, Inc. G-csf conjugates
EP1982732A3 (de) 2000-02-11 2011-06-08 Bayer HealthCare LLC Faktor VII- oder VIIA-ähnliche Konjugate
HRP20030426A2 (en) * 2000-12-06 2005-04-30 Applied Research Systems Ars Holding N.V. Use of sarp-1 for the treatment and/or preventionof scleroderma
PL367154A1 (en) 2001-02-27 2005-02-21 Maxygen Aps New interferon beta-like molecules
JP2005508365A (ja) * 2001-10-29 2005-03-31 ネクター セラピューティックス エイエル,コーポレイション プロテインキナーゼcインヒビターのポリマー結合体
DK3025726T3 (da) * 2002-01-18 2019-12-09 Biogen Ma Inc Polyalkylenpolymerforbindelser og anvendelser deraf
BR0311978A (pt) 2002-06-21 2005-03-22 Novo Nordisk Healthcare Ag Preparação, método para preparar a mesma, formulação farmacêutica, métodos para tratar de uma sìndrome responsiva ao fator vii, para prevenir hemorragias indesejáveis, para prevenir coagulação sanguìnea indesejável e para prevenir as reações mediadas pelo fator tecidual, e, uso de uma preparação
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
AU2003303636B2 (en) * 2002-12-26 2010-08-05 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
CN102319437B (zh) * 2002-12-26 2017-10-13 山景医药公司 具有增强的生物学效用的干扰素‑β的聚合物缀合物
EP2263684A1 (de) 2003-10-10 2010-12-22 Novo Nordisk A/S IL-21 Derivate
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
CN103755800B (zh) 2004-02-02 2016-02-24 Ambrx公司 经修饰的人类生长激素多肽与其用途
AU2005319099B2 (en) 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
CN102532321B (zh) 2004-06-18 2018-10-12 Ambrx公司 新颖抗原结合多肽和其用途
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
AU2005323106B2 (en) 2004-12-22 2010-07-29 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
KR101224781B1 (ko) 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
NZ555425A (en) 2004-12-22 2010-04-30 Ambrx Inc Compositions of aminoacyl-tRNA synthetase and uses thereof
WO2006133088A2 (en) 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
CA2618878C (en) 2005-08-18 2016-06-28 Ambrx, Inc. Compositions of trna and uses thereof
EP1951890A4 (de) 2005-11-16 2009-06-24 Ambrx Inc Verfahren und zusammensetzungen mit nichtnatürlichen aminosäuren
KR20090042755A (ko) 2006-02-28 2009-04-30 닥터 레디즈 레버러토리즈 (이유) 리미티드 폴리에틸렌 글리콜 카보네이트의 제조방법
US20090252720A1 (en) 2006-05-24 2009-10-08 Novo Nordisk Health Care Ag Prolonged FIX Analogues and Derivatives
WO2008030558A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
PT2064333E (pt) 2006-09-08 2014-06-09 Ambrx Inc Supressor híbrido arnt para células de vertebrados
ES2457527T3 (es) 2006-09-08 2014-04-28 Ambrx, Inc. ARNt Supresor hibrido en células de vertebrados
EP2113009B1 (de) * 2007-02-22 2018-11-21 Biovectra Inc. Verfahren zur aufreinigung wasserlöslicher polymere
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 fgf-21 폴리펩티드 및 그 용도
KR20100019467A (ko) 2007-05-02 2010-02-18 암브룩스, 인코포레이티드 변형된 인터페론 베타 폴리펩티드 및 그의 용도
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
MX2011000859A (es) 2008-07-23 2011-02-24 Ambrx Inc Polipeptidos g-csf bovinos modificados y sus usos.
NO2337846T3 (de) 2008-09-26 2018-06-16
PL2342223T3 (pl) 2008-09-26 2017-09-29 Ambrx, Inc. Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
EP2516455A4 (de) 2009-12-21 2013-05-22 Ambrx Inc Modifizierte schweine-somatotropin-polypeptide und deren verwendungen
US9815876B2 (en) 2010-03-05 2017-11-14 Omeros Corporation Chimeric inhibitor molecules of complement activation
US20120135912A1 (en) 2010-05-10 2012-05-31 Perseid Therapeutics Llc Polypeptide inhibitors of vla4
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
SMT201900495T1 (it) 2010-08-17 2019-11-13 Ambrx Inc Polipeptidi di relaxina modificati e loro usi
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
US9382305B2 (en) 2011-07-01 2016-07-05 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
JP6498600B2 (ja) 2012-06-08 2019-04-10 ストロ バイオファーマ インコーポレーテッド 部位特異的な非天然アミノ酸残基を含む抗体、その調製方法、及びその使用方法
EP2863955B1 (de) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modifizierte fc-proteine mit nichtnatürlichen ortsspezifische aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung
US9395468B2 (en) 2012-08-27 2016-07-19 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
DK2890402T3 (da) 2012-08-31 2019-07-15 Sutro Biopharma Inc Modificerede aminosyrer omfattende en azidogruppe
WO2014138720A1 (en) * 2013-03-08 2014-09-12 University Of Southern California Usc Stevens Vinylsulfone-based 18f-labeling compositions and methods and uses thereof
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
AU2014348502B2 (en) 2013-11-15 2019-08-15 Tangible Science, Inc. Contact lens with a hydrophilic layer
BR112017008157A2 (pt) 2014-10-24 2017-12-19 Bristol Myers Squibb Co polipeptídeos de fgf-21 modificados e usos dos mesmos
EP3229851A4 (de) 2014-12-09 2018-08-01 Tangible Science LLC Beschichtung einer medizinischen vorrichtung mit biokompatibler schicht
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
MX2021002575A (es) 2018-09-11 2021-06-08 Ambrx Inc Conjugados de polipeptidos de interleucina-2 y sus usos.
AU2019361206A1 (en) 2018-10-19 2021-06-03 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
CN119455003A (zh) 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
EP4028159A1 (de) 2019-09-10 2022-07-20 Pierce Biotechnology, Inc. Probenvorbereitungszusammensetzungen, vorrichtungen, systeme und verfahren
WO2021183832A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
MX2023011480A (es) 2021-04-03 2023-12-06 Ambrx Inc Conjugados anticuerpo anti-her2-fármaco y usos de estos.
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004203A1 (en) * 1987-11-10 1989-05-18 North Carolina State University Chromatography apparatus and method and material for making the same
US5094960A (en) * 1988-10-07 1992-03-10 New York Blood Center, Inc. Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5645717A (en) * 1989-01-13 1997-07-08 Bio-Rad Laboratories, Inc. Hydrophobic polymers from water-soluble monomers and their use as chromatography media
IL95031A (en) * 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
GEP20033082B (en) * 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
DK0594772T3 (de) * 1991-07-04 1997-02-24 Immunodex K S
US5424063A (en) * 1992-01-09 1995-06-13 The Dow Chemical Company Narrow poly- and mono-dispersed anionic oligomers, and their uses, formulations and process
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
EP0622394A1 (de) * 1993-04-30 1994-11-02 S.A. Laboratoires S.M.B. Umkehrbare Modifikation von Verbindungen, Schwefel enthaltend, mit Polyalkylengycol und ihre Verwendung
JP3583429B2 (ja) * 1993-07-16 2004-11-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 疎水クロマトグラフィーのための分離剤
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5476643A (en) * 1993-11-19 1995-12-19 Bernel Chemical Co. Method of dispersing micronized TIo2, ZnO and other pigments
DE19517848A1 (de) * 1995-05-16 1996-11-21 Merck Patent Gmbh Fluorhaltige Benzoylguanidine
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols

Also Published As

Publication number Publication date
CA2248006C (en) 2002-05-28
ES2206616T3 (es) 2004-05-16
AU720399B2 (en) 2000-06-01
EP0906122B1 (de) 2003-09-10
PT906122E (pt) 2003-12-31
WO1997032607A2 (en) 1997-09-12
US5935564A (en) 1999-08-10
JP2000506851A (ja) 2000-06-06
US5747639A (en) 1998-05-05
AU1410897A (en) 1997-09-22
EP0906122A2 (de) 1999-04-07
DE69629949D1 (de) 2003-10-16
WO1997032607A3 (en) 1997-11-13
CA2248006A1 (en) 1997-09-12
DK0906122T3 (da) 2004-01-19
DE69629949T2 (de) 2004-07-22

Similar Documents

Publication Publication Date Title
DE69629949D1 (de) Aktivierte verbindungen und verfahren zur herstellung und reiningung
DE60132094D1 (de) Verfahren zur Herstellung von gereinigten Partikeln
DE69424123D1 (de) Verfahren zur Reinigung von Schwefeldioxid enthaltendem Gas
ATE278785T1 (de) Neues verfahren zur gewinnung und reinigung von fusionsproteinen
BR9916101A (pt) Purificação de compostos de ciclopeptìdeos equinocandinos
ATE214612T1 (de) Biologisch aktive substanzen, verfahren zur herstellung und sie enthaltende zusammensetzungen
DE59603541D1 (de) Verfahren zur Reinigung von Bisphenol-A
DE69502313D1 (de) Verfahren zur biologischen Reinigung von Gasströmen
NZ308862A (en) Method for purifying thrombopoietin (tpo)
EP0589393A3 (de) Verfahren zur Reinigung von Sauerstoffreichem Abgas.
DE59102062D1 (de) Verfahren zur biologischen Reinigung von Abluftströmen.
ATE509028T1 (de) Ionen-austausch-chromatographische trennung von glp-1 und verwandten peptiden
DE59603826D1 (de) Verfahren zur kontinuierlichen Herstellung von macrocyclischen Verbindungen
ATE321773T1 (de) Semisynthetisches verfahren zur herstellung von didemninanalogen
ATE248631T1 (de) Einstufige vorrichtung und verfahren zur konzentration und säuberung biologischer moleküle
ATE339389T1 (de) Verfahren zur reinigung von kerzenfiltern und membrananlagen
DE59309127D1 (de) Verfahren zur Reaktivierung von gereinigten Membranproteinen
ATE215968T1 (de) Verfahren zur reinigung von thrombomodulin
DE69519203D1 (de) Verfahren zur Herstellung von Extrakten enthaltende polyphenalische oligomere Verbindungen von Catechin-Typ, aus pflanzenartigen Quellen, und diese erhaltene Extrakte
DE69623068D1 (de) Verfahren zur Reinigung von Polysaccharid
MXPA05011577A (es) Purificacion de afinidad a ciclodextrina.
ATE97888T1 (de) Filterkoerper und verfahren zur herstellung eines filterkoerpers.
ATE224907T1 (de) Verfahren zur reinigung von roxithromycin
ID26405A (id) Pemurnian karboksaldehida
DE69710628D1 (de) Verfahren zur Reinigung proteinhaltiger Abwässer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0906122

Country of ref document: EP

REN Ceased due to non-payment of the annual fee